Rofecoxib for dysmenorrhoea: meta-analysis using individual patient data
article
OA: gold
CC0
⤵ 2 in-corpus citations
Abstract
BACKGROUND: Individual patient meta-analysis to determine the analgesic efficacy and adverse effects of single-dose rofecoxib in primary dysmenorrhoea. METHODS: Individual patient information was available from three randomised, double blind, placebo and active controlled trials of rofecoxib. Data were combined through meta-analysis. Number-needed-to-treat (NNT) for at least 50% pain relief and the proportion of patients who had taken rescue medication over 12 hours were calculated. Information was collected on adverse effects. RESULTS: For single-dose rofecoxib 50 mg compared with placebo, the NNTs (with 95% CI) for at least 50% pain relief were 3.2 (2.4 to 4.5) at six, 3.1 (2.4 to 9.0) at eight, and 3.7 (2.8 to 5.6) at 12 hours. For naproxen sodium 550 mg they were 3.1 (2.4 to 4.4) at six, 3.0 (2.3 to 4.2) at eight, and 3.8 (2.7 to 6.1) at 12 hours. The proportion of patients who needed rescue medication within 12 hours was 27% with rofecoxib 50 mg, 29% with naproxen sodium 550 mg, and 50% with placebo. In the single-dose trial, the proportion of patients reporting any adverse effect was 8% (4/49) with rofecoxib 50 mg, 12% (6/49) with ibuprofen 400 mg, and 6% (3/49) with placebo. In the other two multiple dose trials, the proportion of patients reporting any adverse effect was 23% (42/179) with rofecoxib 50 mg, 24% (45/181) with naproxen sodium 550 mg, and 18% (33/178) with placebo. CONCLUSIONS: Single dose rofecoxib 50 mg provided similar pain relief to naproxen sodium 550 mg over 12 hours. The duration of analgesia with rofecoxib 50 mg was similar to that of naproxen sodium 550 mg. Adverse effects were uncommon suggesting safety in short-term use of rofecoxib and naproxen sodium. Future research should include restriction on daily life and absence from work or school as outcomes.
My notes (saved in your browser only)
Condition tags
Citation neighborhood
Papers in the corpus that this work cites (lower rings, blue) and that cite this one (upper rings, green). Dot size scales with the paper's in-corpus citation count — bigger dot = more influential within the endo/adeno field. Click a dot to open that paper. [ expand to 2 hops ] — adds papers reached through this work's immediate citers/citees. Heavier; up to 60 extra dots.
References (32)
- Analgesic Efficacy of Etoricoxib in Primary Dysmenorrhea: Results of a Randomized, Controlled Trial via openalex
- Dysmenorrhea treatment with a single daily dose of rofecoxib via openalex
- Increased concentrations of eicosanoids and platelet-activating factor in menstrual blood from women with primary dysmenorrhea. via openalex
- Nonsteroidal antiinflammatory drugs and reproduction via openalex
- Valdecoxib, a cyclooxygenase-2-specific inhibitor, is effective in treating primary dysmenorrhea via openalex
- W1986215651 via openalex
- W2000442546 via openalex
- W2001090887 via openalex
- W2032378252 via openalex
- W2038075430 via openalex
- W2038693293 via openalex
- W2041221488 via openalex
- W2058055588 via openalex
- W2080197694 via openalex
- W2085798593 via openalex
- W2086481317 via openalex
- W2090362854 via openalex
- W2090642049 via openalex
- W2092233783 via openalex
- W2092854192 via openalex
- W2097561978 via openalex
- W2111149452 via openalex
- W2116446898 via openalex
- W2163501394 via openalex
- W2164796644 via openalex
- W2170973793 via openalex
- W2595437246 via openalex
- W4400801783 via openalex
- W1480729244 via openalex
- W1489868193 via openalex
- W1967959895 via openalex
- W1977100984 via openalex
Cited by (2)
Source provenance
- openalex
- last seen: 2026-06-10T17:14:06.276822+00:00
License: CC0
· commercial use OK